Cargando…
The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2
The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in numerous deaths worldwide, along with devastating economic disruptions, and has posed unprecedented challenges to healthcare systems around the world. I...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588549/ https://www.ncbi.nlm.nih.gov/pubmed/37868494 http://dx.doi.org/10.7759/cureus.45602 |
_version_ | 1785123607182049280 |
---|---|
author | Jamous, Yahya F Alhomoud, Dalal A |
author_facet | Jamous, Yahya F Alhomoud, Dalal A |
author_sort | Jamous, Yahya F |
collection | PubMed |
description | The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in numerous deaths worldwide, along with devastating economic disruptions, and has posed unprecedented challenges to healthcare systems around the world. In the wake of COVID-19's emergence in 2019, a variety of vaccine technologies were formulated and developed, including those that drew from the technology employed in messenger RNA (mRNA) vaccines, designed to curb the disease's transmission and manage the pandemic. mRNA vaccine has several advantages over traditional ones, and hence its development has received considerable attention recently. Researchers believe the mRNA vaccine technology will emerge as the leading technology because it is potent, inexpensive, rapidly developed, and safe. This article provides an overview of mRNA vaccines with a special focus on the efficacy and safety of the Moderna and Pfizer-BioNTech mRNA vaccines against the different variants of COVID-19 and compare them with the Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines. The clinical data reviewed in this article demonstrate that the currently authorized Moderna and Pfizer-BioNTech mRNA vaccines are highly safe and potent against different variants of COVID-19, especially in comparison with Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines. |
format | Online Article Text |
id | pubmed-10588549 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-105885492023-10-21 The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2 Jamous, Yahya F Alhomoud, Dalal A Cureus Epidemiology/Public Health The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in numerous deaths worldwide, along with devastating economic disruptions, and has posed unprecedented challenges to healthcare systems around the world. In the wake of COVID-19's emergence in 2019, a variety of vaccine technologies were formulated and developed, including those that drew from the technology employed in messenger RNA (mRNA) vaccines, designed to curb the disease's transmission and manage the pandemic. mRNA vaccine has several advantages over traditional ones, and hence its development has received considerable attention recently. Researchers believe the mRNA vaccine technology will emerge as the leading technology because it is potent, inexpensive, rapidly developed, and safe. This article provides an overview of mRNA vaccines with a special focus on the efficacy and safety of the Moderna and Pfizer-BioNTech mRNA vaccines against the different variants of COVID-19 and compare them with the Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines. The clinical data reviewed in this article demonstrate that the currently authorized Moderna and Pfizer-BioNTech mRNA vaccines are highly safe and potent against different variants of COVID-19, especially in comparison with Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines. Cureus 2023-09-20 /pmc/articles/PMC10588549/ /pubmed/37868494 http://dx.doi.org/10.7759/cureus.45602 Text en Copyright © 2023, Jamous et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Epidemiology/Public Health Jamous, Yahya F Alhomoud, Dalal A The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2 |
title | The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2 |
title_full | The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2 |
title_fullStr | The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2 |
title_full_unstemmed | The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2 |
title_short | The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2 |
title_sort | safety and effectiveness of mrna vaccines against sars-cov-2 |
topic | Epidemiology/Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588549/ https://www.ncbi.nlm.nih.gov/pubmed/37868494 http://dx.doi.org/10.7759/cureus.45602 |
work_keys_str_mv | AT jamousyahyaf thesafetyandeffectivenessofmrnavaccinesagainstsarscov2 AT alhomouddalala thesafetyandeffectivenessofmrnavaccinesagainstsarscov2 AT jamousyahyaf safetyandeffectivenessofmrnavaccinesagainstsarscov2 AT alhomouddalala safetyandeffectivenessofmrnavaccinesagainstsarscov2 |